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Abstract
Influenza A viruses have a wide host range for infection, from wild
waterfowl to poultry to humans. Recently, the cross-species
transmission of avian influenza A, particularly subtype H5N1, has
highlighted the importance of the non-human subtypes and their
incidence in the human population has increased over the past
decade. During cross-species transmission, human disease can
range from the asymptomatic to mild conjunctivitis to fulminant
pneumonia and death. With these cases, however, the risk for
genetic change and development of a novel virus increases,
heightening the need for public health and hospital measures. This
review discusses the epidemiology, host range, human disease,
outcome, treatment, and prevention of cross-transmission of avian
influenza A into humans.
Introduction
Human influenza pandemics over the last 100 years have
been caused by H1, H2, and H3 subtypes of influenza A
viruses. More recently, avian influenza virus subtypes (that is,
H5, H7) have been found to directly infect humans from their
avian hosts. The recent emergence, host expansion, and
spread of a highly pathogenic avian influenza (HPAI) H5N1
subtype in Asia have heightened concerns globally, both in
regards to mortality from HPAI H5N1 infection in humans and
the potential of a new pandemic. This paper will review the
current human infections with avian influenza and their public
health and medical implications.
Influenza A viruses
Influenza A, B and C are the most important genera of the
Orthomyxoviridae family, casusing both pandemic and
seasonal disease in humans. Influenza A viruses are
enveloped, single-stranded RNA viruses with a segmented
genome (Table 1) [1]. They are classified into subtypes on
the basis of the antigenic properties of the hemagglutinin
(HA) and neuraminidase (NA) glycoproteins expressed on the
surface of the virus [1,2]. Influenza A viruses are
characterized by their pathogenicity, with highly pathogenic
avian influenza (HPAI) causing severe disease or death in
domestic poultry [3]. Molecular changes in the RNA genome
occur through two main mechanisms: point mutation
(antigenic drift) and RNA segment reassortment (antigenic
shift) [4,5]. Point mutations cause minor changes in the
antigenic character of viruses and are the primary reason a
vaccination for influenza A is given yearly. Reassortment
occurs when a host cell is infected with two or more influenza
A viruses, leading to the creation of a novel subtype. The
influenza subtypes of the 1957 (H2N2) and 1968 (H3N2)
pandemics occurred through reassortment, while the origins
of the 1918 (H1N1) pandemic are unclear.
The HA glycoprotein mediates attachment and entry of the
virus by binding to sialic acid receptors on the cell surface.
The binding affinity of the HA to the host sialic acid allows for
the host specificity of influenza A [6,7]. Avian influenza
subtypes prefer to bind to sialic acid linked to galactose by
α-2,3 linkages, which are found in avian intestinal and
respiratory epithelium (Table 2) [8]. Human virus subtypes
bind to α-2,6 linkages found in human respiratory epithelium
[8,9]. Swine contain both α-2,3 and α-2,6 linkages in their
respiratory epithelium, allowing for easy co-infection with both
human and avian subtypes (thus acting as a ‘mixing vessel’
for new strains) [10]. Humans have been found to contain
both α-2,3 and α-2,6 linkages in their lower respiratory tract
and conjunctivae, which allows for human infections by avian
subtypes [9,11,12]. The HA glycoprotein is the main target
for immunity by neutralizing antibodies.
The NA glycoprotein allows the spread of the virus by
cleaving the glycosidic linkages to sialic acid on host cells
and the surface of the virus. The virus is then spread in
secretions or other bodily fluids. The NA glycoprotein is not
the major target site for neutralization of the virus by antibodies. 
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Host range of influenza A viruses
Influenza A viruses infect a wide range of hosts, including
many avian species, and various mammalian species, such as
swine, ferrets, felids, mink, whales, horses, seals, dogs,
civets, and humans [13-31]. Wild birds (ducks, geese,
swans, and shorebirds) are important natural reservoirs of
these viruses, and all of the known 16 HA and 9 NA subtypes
have been found in these birds [32-35]. In most cases, these
subtypes are found within the gastrointestinal tract of the
birds, are shed in their feces, and rarely cause disease [32].
Since 2002, however, HPAI H5N1 viruses originating in Asia
have been reported from approximately 960 wild bird
species, causing disease in some instances and asympto-
matic shedding in others [36-48]. The virus has now spread
across Asia, Europe, the Middle East, and some African
countries. Additional species, such as tigers, leopards, cats,
stone martens, and humans have also become infected with
HPAI H5N1 [49]. This spread of H5N1 into a wide range of
animal and avian species may enhance the spread of the virus
into the human population as it interacts with animals in a
number of ways (increased land use, markets, consumption)
[44]. Thus, the potential contact, transmission, and mutability
of HPAI H5N1 worldwide will increase as the number of
species and their interactions increase, complicating
prevention, surveillance and treatment possibilities.
Epidemiology and pathogenicity of avian
influenza infections in humans
The incidence of avian influenza infections in humans has
increased over the past decade (Table 3). Initially, cases of
avian influenza (H7N7) in humans occurred in association
with poultry outbreaks, manifesting as self-limiting
conjunctivitis [30,50-53]. Then, in 1997, a large scale HPAI
H5N1 outbreak occurred among poultry in Hong Kong, with
18 documented human cases [29,31,54,55]. Two
subsequent poultry outbreaks in Hong Kong in 1999 and
2003 with HPAI H5N1 occurred without human cases until
2003 when two members of a family in Hong Kong
contracted HPAI H5N1 [56]. In December of 2003, HPAI
H5N1 surfaced in poultry in Korea and China, and from 2003
to 2006 the outbreak stretched worldwide in the largest
outbreak in poultry history. Human cases of HPAI H5N1
followed the poultry outbreak, with a total of 256 cases and
151 fatalities thus far [57]. Other limited outbreaks have
occurred, causing variable human disease (Table 3) [52,58].
However, HPAI H5N1 remains the largest and most
significant poultry and human avian influenza outbreak.
Epidemiological investigations of human cases of avian
influenza show that the virus was acquired by direct contact
with infected birds [29-31,50-56]. Influenza A is transmitted
through the fecal-oral and respiratory routes among wild birds
and poultry [32]. Human interaction with these infected
secretions and birds was the major mode of transmission,
with contact including consumption of undercooked or raw
poultry products, handling of sick or dead birds without
protection, or food processing at bird cleaning sites. All birds
were domesticated (chicken, duck, goose) and no
transmission from birds in the wild (migrating) or
Table 1
Characteristics of influenza viruses 
Influenza A Influenza B Influenza C
Genetic structure 8 segments 8 segments 7 segments
Viral proteins 10 total 11 total 9 total
Unique viral protein M2 NB HEF
Antigenic determinants Hemagglutinin and neuroaminidase Hemagglutinin and neuroaminidase Hemagglutinin and neuroaminidase
Genetic change Antigenic shift and drift Antigenic drift Antigentic drift
Host range Avians, humans swine,  Humans Humans and swine
marine mammals, horses
Human epidemiology Pandemics and seasonal epidemics Seasonal epidemics No seasonality
Table 2
Characteristics and pathogenicity of influenza A viruses
Viral features
Number of HA subtypes 16
Number of NA subtypes 9
Predominant human subtypes H1, H2, H3
Avian subtypes H1-H16
HPAI subtypes H5 and H7
Conversion to HPAI  Basic amino acid insertion in HA
Avian sialic acid-galactose linkages α-2,3 linkages
Human sialic acid-galactose linkages α-2,6 linkages
HA, hemagglutinin; HPAI, highly pathogenic avian influenza; NA,
neuroaminidase.Page 3 of 9
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contaminated waterways has been documented. In a few
cases, limited human to human transmission has been
reported among health care workers and family members
(Table 4) [59-63]. In each of these cases, no personal
protective equipment was used, which is the major factor in
transmission between humans [60].
Clinical manifestations of avian influenza in
humans
The clinical manifestations of avian influenza in humans has
ranged from mild conjunctivitis to severe pneumonia with
multi-organ system failure (Table 5) [50,51]. The median age
of patients was 17.2 years in the 1997 HPAI H5N1 outbreak
and 16 years in the 2003 to 2006 Southeast Asian cases
(range 2 months to 90 years) [17,55,65-68]. The incubation
period ranged from two to eight days from contact with sick
or dead birds to symptom onset. The predominant clinical
findings appear to vary with each influenza A subtype; for
example, in 2003 during the Netherlands outbreak (H7N7)
92% (82 of 89) of patients presented with conjunctivitis and
a minority with respiratory symptoms [53]. However, with
HPAI in Hong Kong in 1997 and in Southeast Asia currently,
pneumonia progressing to multiorgan failure, acute
respiratory distress syndrome (ARDS), and death are the
predominant findings [17,55,65-68]. Rye syndrome, pulmo-
nary hemorrhage, and predominant nausea, vomiting, and
diarrhea complicate these cases [68]. Laboratory findings
include both thrombocytopenia and lymphopenia [65,66].
Chest radiographic findings include interstitial infiltrates, lobar
consolidation, and air bronchograms. The clinical course of
patients with HPAI H5N1 is rapid, with 68% percent of
patients developing ARDS and multiorgan failure within
6 days of disease onset [69]. The case fatality rate ranges
form 67% to 80%, depending on the case series
[17,55,65,66]. Once the patients reached the critical care
unit, however, the mortality rate was 90% [69]. The average
time of death from disease onset was nine to ten days.
Avian influenza A infections in humans differ from seasonal
influenza in several ways. The presence of conjunctivitis is
Available online http://ccforum.com/content/11/2/209
Table 3
Avian influenza A outbreaks reported in humans
Worldwide 
(Southeast Asia, 
United Kingdom  Hong Kong  Hong Kong  The Netherlands  Canada  Africa, Middle East) 
1995  1997  1999  2003  2004  2003 to present 
[51] [54] [52] [53] [58] [57,65,66,68]
Influenza A subtype H7N7 H5N1 H9N2 H7N7 H7N3 H5N1
Source of infection Poultry Poultry and  Poultry Poultry Poultry Poultry and 
waterfowl waterfowl
Clinical presentation Conjunctivitis Conjunctivitis  ILI Conjunctivitis,  Conjunctivitis,  Conjunctivitis, ILI, 
and ILI pneumonia, ILI ILI pneumonia, 
multi-organ failure
Number of human cases 1 18 2 89 2 256
Number of fatalities (percent) 0 (0) 6 (33) 0 (0) 1 (1) 0 (0) 151 (59)
H, hemagglutinin; ILI, influenza like illness; N, neuroaminidase.
Table 4
Person to person transmission of avian influenza
Hong Kong  Hong Kong  Netherlands  Thailand  Vietnam  Indonesia 
1997 1997 2003 2004 2004 2006
[59] [60] [53] [61] [62] [64]
Influenza subtype H5N1 H5N1 H7N7 H5N1 H5N1 H5N1
Location Household Hospital Household Hospital Hospital Household
Transmission to Family  Health care Family Family Health Care  Family
member worker member member worker member
Number of cases 1 8 3 2 0 7
Clinical presentation Seropositive Seropositive Conjunctivitis  Pneumonia,  N/A Pneumonia, 
and ILI death death
ILI, influenza like illness.more common with avian influenza A infections than with
seasonal influenza. Gastrointestinal symptoms, as seen with
HPAI H5N1, and reports of primary influenza pneumonia and
development of ARDS are also more common with avian
influenza A infections [65,67,69]. Finally, the rapid progres-
sion to multi-organ failure and eventually death occurs at a
much higher rate with avian influenza A infections [69].
Post-mortem studies have illustrated findings consistent with
an overwhelming systemic inflammatory response syndrome,
including diffuse alveolar damage, acute tubular necrosis and
atrophy, disseminated intravascular coagulation, and multi-
organ damage [70,71]. Interestingly, the virus has been
isolated from the lungs, intestine, spleen, and brain, suggest-
ing viremia, but active replication of the virus has been limited
to the lungs [71]. This overwhelming inflammatory response,
with acute lung injury and ARDS as the predominant features,
coincides with the findings of preferential binding of the avian
influenza A viruses to α-2,3 linkages in type II pneumocytes of
the lower respiratory tract of humans and a vigorous cytokine
response, including increased interleukin-6, interleukin-10,
and interferon beta release [11,12,70,71].
Diagnosis
The clinical diagnosis of avian influenza infection in humans is
difficult and relies on the epidemiological link to endemic
areas, contact with sick or dead poultry, or contact with a
confirmed case of avian influenza (Table 6). Since many
infectious diseases present with similar symptoms, the only
feature significant to the clinician may be contact in an
endemic area, through travel or infected poultry, and the
clinician should always elicit a detailed patient history.
The definitive diagnosis is made from isolation of the virus in
culture from clinical specimens. This method not only
provides the definitive diagnosis, but the viral isolate is now
available for further testing, including pathogenicity, antiviral
resistance, and DNA sequencing and analysis. Alternatively,
antibody testing can be performed, with a standard four-fold
titer increase to the specific subtype of avian influenza virus.
Neutralizing antibody titer assays for H5, H7 and H9 are
performed by the micorneutralization technique [72]. Western
blot analysis with recombinant H5 is the confirmatory test for
any positive microneutralization assay [59,60,72]. More
recently, rapid diagnosis can be performed with reverse
transcription-PCR on clinical samples with primers specific
for the viral subtype [73-75]. This test should be performed
only on patients meeting the case definition of possible avian
influenza A infection.
Any suspected case of avian influenza in a human should be
investigated by the public health officials in the province or
country of origin [39,76]. Additionally, governmental labs are
often equipped with the appropriate biolevel safety 3
laboratories, primer libraries, and associated expertise to
confirm the diagnosis quickly and efficiently. Any clinical
specimens should be submitted with the assistance of the
public health experts.
Treatment
Treatment of avian influenza infections in humans includes
antiviral therapy and supportive care. Controlled clinical trials
on the efficacy of antivirals (NA inhibitors), supportive
therapy, or adjuvant care have never been performed, so
current recommendations stem from the experiences of past
avian influenza outbreaks and animal models.
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Table 5
Clinical, laboratory, and radiographic findings of avian
influenza in humans
Clinical presentation
Conjunctivitis
Influenza-like illness
Nausea
Emesis
Diarrhea
Shortness of breath
Pneumonia
Laboratory findings
Lymphopenia
Thrombocytopenia
Elevated creatinine
Abnormal transaminases
Chest radiographic findings
Interstitial infiltrates
Lobar infiltration
Consolidation
Pneumothorax (on mechanical ventilation)
Table 6
Case definition of avian influenza
Suspected H5N1 case
Lower respiratory tract infection
Fever (>38°C)
Cough
Shortness of breath
AND one of the following in the past 7 days
Close contact with a known or suspected human case of H5N1 
disease
Contact with sick or dead birds (handling) or the environment 
where H5N1 is present
Consumption of a sick or dead bird in an H5N1 endemic area
Contact or exposure to laboratory specimens of H5N1The adamantanes (rimantadine and amantadine) and NA
inhibitors (oseltamivir and zanamivir) are the antivirals used for
treatment and prophylaxis of influenza infections in humans. In
avian influenza virus infections, adamantanes have no role
due to widespread resistance through a M2 protein
alteration. In addition, over 90% of isolates of H1 and H3
human subtypes during seasonal influenza have had
resistance to the adamantanes [77]. Their role has now been
limited to prophylaxis in the community when the circulation
strain is know to be susceptible to the adamantanes [78-80].
NA inhibitors (oseltamivir and zanamivir) have been studied
for both treatment and prophylaxis with the human influenza A
subtypes H1, H2, and H3 as well as influenza B (Table 7)
[80-82]. In animal models with HPAI H5N1, their efficacy has
been well documented, with improved survival rates seen
after infection [83-85]. Oseltamivir has been used in avian
influenza outbreaks involving H7N7 and HPAI H5N1, and
therapy with oseltamivir has been shown to decrease the viral
load in nasal secretions in patients infected with HPAI H5N1
[11,86,87]. Resistance to oseltamivir has been documented
in a HPAI H5N1 subtype in a Vietnamese girl treated with 75
mg daily for 4 days as post-exposure prophylaxis [68]. The
NA glycoprotein had a histidine to tyrosine substitution at
position 274, conveying a markedly higher IC50 for oseltamivir
[68,88]. In one study, the viral count of HPAI H5N1 in nasal
secretions did not decrease with the administration of
oseltamivir when the H5N1 isolate carried this resistance
mutation [68]. However, resistance produced by this change
may be overcome with higher doses of oseltamivir in vitro,
and this change has not been documented to confer
resistance to zanamivir [88].
The timing of treatment with NA inhibitors is paramount, as
early therapy is directly related to improved survival
[66,83-85]. The greatest level of protection was seen if the
NA inhibitors were started within 48 hours of infection, and
protection rapidly dropped after 60 hours [78,79]. These
initial studies, however, were performed with seasonal human
influenza A and B, where the period of viral shedding is
approximately 48 to 72 hours. In HPAI H5N1 cases from
Southeast Asia, survival appeared to be improved in patients
who received oseltamavir earlier (4.5 days versus 9 days after
onset of symptoms) [66]. Both of these time periods are
much longer than documented in animal models, so the
window of optimal therapy is still unknown, particularly if viral
shedding exceeds the average 48 to 72 hour period seen in
seasonal influenza A and B infections.
Combination therapy with influenza A viruses has not been
studied [84]. Ribaviron by inhalation has been evaluated in
vitro with some avian influenza A subtypes and has been
found to reduce mortality from influenza B in a mouse model
[89]. Further animal model studies are indicated to determine
if there is a role for ribaviron or combination therapy with
avian influenza A viruses.
Supportive care with intravenous rehydration, mechanical
ventilation, vasopressor therapy, and renal replacement
therapy are required if multiorgan failure and ARDS are a
feature of disease [69,90]. Due to the progression of
pneumonia to ARDS, non-invasive ventilation is not
recommended, and early intubation may be beneficial before
overt respiratory failure ensues. Corticosteroids have been
used in some patients with HPAI H5N1, but no definitive role
for steroids has been determined. Other immunomodulatory
therapy has not been reported [91].
Vaccination
Human vaccination for avian influenza viruses has not been
widely used, although multiple vaccination trials are
underway. Prior avian vaccines in humans have been poorly
immunogenic and thus have limited use. An inactivated H5N3
has been tested and was tolerated but with limited
immunogenicity [91,92]. Other H5 vaccines have resulted in
the development of neutralizing antibodies, but to a limited
Available online http://ccforum.com/content/11/2/209
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Table 7
Neuroaminidase inhibitors 
Oseltamivir Zanamivir
Spectrum of activity Influenza A and B Influenza A and B
Administration Oral Inhalation
Prophylaxis ≥13 years; 75 mg daily >13 years; 10 mg daily
Treatment ≥1 year; 75 BID × 5 to 10 days ≥7 years; 10 mg BID × 5 to 10 days
Select adverse effects GI symptoms: N/V, abdominal pain Bronchospasm, cough
Resistance potential Drug-resistant strain of H5N1 reported None yet 
Efficacy Estimated efficacy: 30 to 70 percent Not well studied
Generic available No No
Data are from [80-82]. BID, twice a day; GI, gastrointestinal; N/V, nausea and vomiting.degree [93,94]. Recently, a large randomized trial looked at
an H5N1 attenuated vaccine from the Vietnam strain [95].
Only a modest immune response was seen, with micro-
neutralization antibodies being developed at 12 times the
dose used in the seasonal influenza vaccine. The side effects
were minimal. A number of other industry trials with adjuvant
vaccines are currently ongoing. Although promising, human
vaccination against avian influenza viruses is still under
development. Underscoring this development is the
uncertainty of a pandemic strain, which may have vastly
different antigenic properties from any developed H5 vaccine.
Infection control
Health care infection control is a crucial component in the
management of avian influenza infection or a new pandemic
strain. Experience from the severe ARDS outbreak in 2002
has illustrated that appropriate infection control measures are
paramount to reduce spread to health care workers and,
possibly, the community [96-98]. Therefore, the World Health
Organization (WHO) and Centers for Disease Control and
Prevention (CDC) recommend contact and airborne
precautions for any initial suspected case of avian influenza in
a human [99]. In late October 2006, the CDC released
updated interim guidance on the use of masks and
respirators in the health care setting (Table 8) [99]. In certain
high risk procedures, additional protection may be
considered given the likelihood of generating aerosol
particles that may enhance transmission (Table 9) [99].
Respiratory protection should be worn along with an
impermeable gown, face shield, and gloves. Initial cases
should be placed in a negative pressure isolation room with 6
to 12 air changes per hour. Hand hygiene with antibacterial
soap or alcohol based washless gel should be standard, with
appropriate basins at each patient room. Seasonal
vaccination of all health care workers should be preformed
and further emphasized in order to reduce the likelihood of
co-infection with two stains of influenza. Visitors and family
members should be strictly monitored and their access to the
patient limited to reduce the likelihood of spread. Finally,
antiviral chemoprophylaxis should be available to any health
care workers exposed to an infected individual. Any
symptomatic worker should be taken off duty and workplace
surveillance should occur. With these aggressive measures,
risk to health care workers, patients, and family members will
be reduced.
Conclusion
Avian influenza viruses have occurred with increased
incidence within the human population, reflecting the delicate
and tangled interaction between wildlife, domesticated
animals, and humans. Disease in humans can be limited to
conjunctivitis or an influenza-like illness, but HPAI H5N1
causes mainly severe pneumonia, respiratory failure, and
death. Most cases have occurred through direct transmission
from infected poultry or waterfowl, with only a few limited
cases of human to human transmission. Treatment has been
successful with the NA inhibitors if started early, and vaccine
development is underway with a more immunogenic
attenuated H5N1 virus preparation. Infection control
measures are the mainstay for prevention and disease
reduction. Avian influenza viruses may constitute part of the
next pandemic, so appropriate knowledge, prevention, and
treatment will reduce the likelihood of this occurrence.
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